The Fabry program expects top-line data by Q2 2025, with the last patient visit in April 2025. FDA's supportive approach for rare diseases allowed an accelerated approval pathway for positive eGFR slope data.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing